SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylation-Reference-Cited by-同舟云学术

SPARCL1 exhibits different expressions in left- and right-sided colon cancer and is downregulated via DNA methylation

Published:2021-08 Issue:16 Volume:13 Page:1269-1282
ISSN:1750-1911
Container-title:Epigenomics
language:en
Short-container-title:Epigenomics

Author:

Hu Hanguang¹²,Wu Dehao¹,Liu Xibo³,Yu Haifeng²⁴⁵,Xu Junxi⁶,Cai Wen¹⁶,Huang Yanqin¹,Bai Rui¹,Zhang Jiawei¹,Gu Ying⁷,Zheng Shu¹,Ge Weiting¹⁸^ORCID

Affiliation:

1. Cancer Institute, Key Laboratory of Cancer Prevention & Intervention, China National Ministry of Education; Key Laboratory of Molecular Biology in Medical Sciences; the Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China

2. Department of Oncology, the Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, China

3. Department of Pathology, Shaoxing People's Hospital, No. 568, Zhongxing North Road, Shaoxing, 312000, Zhejiang Province, China

4. Department of Lymphatic Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310005, Zhejiang Province, China

5. Institute of Cancer & Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang Province, China

6. Department of Gastroenterology, the Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, China

7. Institute of genetics, Zhejiang University, Zijingang Campus of Zhejiang University, Yuhangtang Road No.388, Hangzhou, 310058, Zhejiang Province, China

8. Cancer Center, Zhejiang University, Hangzhou, 310000, Zhejiang Province, China

Abstract

Aim: The authors previously found that SPARCL1 functions to suppress colorectal cancer metastasis. Here, the epigenetic mechanism of SPARCL1 regulation and its relationship with clinicopathological features in colon cancer were investigated. Materials & methods: SPARCL1 expression was evaluated by immunohistochemistry staining in a tissue array containing 271 left-sided colon cancer samples and 257 right-sided colon cancer samples. In vivo and in vitro DNA methylation states were measured by biochemical sulfide potential assay. The transcription and DNA methylation states in cells were altered by siRNA or decitabine treatment, respectively. Cellular motility properties were compared through transwell assay. Results & conclusion: SPARCL1, mediated by its DNA methylation, may arrest colorectal carcinoma motility. Furthermore, SPARCL1 expression is higher and may have a specific prognostic value in left-sided colon cancer.

Funder

The National Key R&D Program of China

The Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

The Basic Public Welfare Research Project of Zhejiang Province

Publisher

Future Medicine Ltd

Subject

Cancer Research,Genetics

Link

https://www.futuremedicine.com/doi/pdf/10.2217/epi-2021-0231

Reference43 articles.